Search results
FDA Approves Takeda’s Subcutaneous Form of Entyvio as a Maintenance Therapy in Adults with...
Pharmaceutical Executive Magazine· 5 days agoThe FDA has approved Takeda Pharmaceuticals’ subcutaneous (SC) form of Entyvio (vedolizumab) as a...
FDA approves Takeda’s self-administered Entyvio for Crohn’s disease
BioPharma-Reporter· 1 day agoThe new formulation is taken as a maintenance therapy following induction with intravenous (IV) ...
FDA approves Takeda's ENTYVIO for Crohn's disease
Investing.com· 7 days agoFDA approves Takeda's ENTYVIO for Crohn's disease
How Is Ulcerative Colitis Treated?
Health via Yahoo News· 6 days agoAnti-TNF agents reduce inflammation and UC symptoms. Integrin receptor agonists: Tysabri (natalizumab) and Entyvio (vedolizumab) prevent inflammatory cells from moving into ...
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 1 day agoMoreover, thanks to the steps taken by the company's CEO to optimize administrative and general expenses, label expansions for Adcetris and Takhzyro, as...
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease
Morningstar· 6 days agoTakeda Pharmaceutical said the U.S. Food and Drug Administration has approved subcutaneous administration of Entyvio as a maintenance therapy for adults with Crohn's disease ...
FDA OKs Sub-Q Vedolizumab for Crohn's Maintenance Therapy
Medscape· 6 days agoSubcutaneous administration of vedolizumab is now approved for maintenance therapy in adults with moderate to severe active Crohn's disease after induction therapy with intravenous vedolizumab.
ED Doc's License Revoked; Bird Flu Fatality Rate in Humans; Pesticide Risk in Fruits
MedPage Today· 6 days agoNew Jersey revoked the medical license of emergency department (ED) doctor Shar Kennett, MD, to...
